PYPB Stock Chart & Stats
€0.08
€0.00(0.00%)
At close: 4:00 PM EDT
€0.08
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.07 - €0.15
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€26.11M
Enterprise Value€6.18M
Total Cash (Recent Filing)€1.68M
Total Debt (Recent Filing)€559.00K
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Dec 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding218,974,290
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.01
Price to Sales (P/S)1.81
P/FCF Ratio-12.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue VisibilityThe record order book and approximately 95% coverage of annual guidance provide unusually strong near-term revenue visibility for a project-based service business. This supports planning, resource utilization and conversion of signed work into revenue over the next several quarters.
Margin ImprovementA 53% gross margin, supported by increased Phase II/III work and automated analysis, indicates potential operating leverage as activity scales. If this mix persists, it can improve the economics of contracted services and reduce the gap between revenue growth and profitability.
Strategic Commercial PartnershipIntegration with Medidata’s Rave platform creates a potentially scalable distribution channel for IXICO’s analytics and supports its productization strategy. Access to a platform used across much of FDA-approved drug development could strengthen commercial reach and recurring-revenue potential.
Bears Say
Persistent LossesThe continuing EBITDA loss means revenue growth has not yet produced sustainable earnings, while management’s 2029 target implies a lengthy transition before profitability. Ongoing investment may therefore continue to consume resources and constrain near-term financial resilience.
Weak Cash GenerationNegative operating cash flow shows that the current service model is not consistently converting activity into internally generated cash. Volatile free cash flow can limit funding flexibility and increase reliance on disciplined spending or external financing while the company scales.
Trial And Productization Timing RiskIXICO’s contracted work remains exposed to clinical-trial descopes and cancellations, while its TechBio strategy may take at least two years to deliver meaningful monetized recurring revenue. This creates execution uncertainty between current demand and longer-term growth ambitions.
IXICO plc News
PYPB FAQ
What was IXICO PLC’s price range in the past 12 months?
IXICO PLC lowest stock price was €0.07 and its highest was €0.15 in the past 12 months.
What is IXICO PLC’s market cap?
IXICO PLC’s market cap is €26.11M.
When is IXICO PLC’s upcoming earnings report date?
IXICO PLC’s upcoming earnings report date is Dec 08, 2026 which is in 42 days.
How were IXICO PLC’s earnings last quarter?
IXICO PLC released its earnings results on May 19, 2026. The company reported -€0.014 earnings per share for the quarter.
Is IXICO PLC overvalued?
According to Wall Street analysts IXICO PLC’s price is currently Overvalued.
Does IXICO PLC pay dividends?
IXICO PLC does not currently pay dividends.
What is IXICO PLC’s EPS estimate?
IXICO PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IXICO PLC have?
IXICO PLC has 218,974,290 shares outstanding.
What happened to IXICO PLC’s price movement after its last earnings report?
IXICO PLC reported an EPS of -€0.014 in its last earnings report. Following the earnings report the stock price went up 1.515%.
Which hedge fund is a major shareholder of IXICO PLC?
Currently, no hedge funds are holding shares in DE:PYPB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IXICO PLC
IXICO plc, a London-based company established in 1995, specializes in providing data analytics services to the global biopharmaceutical industry. Operating across the UK, Europe (including Switzerland, Netherlands, Ireland), the United States, and internationally, IXICO supports clinical trials by managing the entire lifecycle of study-generated data, from acquisition and processing to in-depth analysis and comprehensive reporting. They leverage proprietary technology platforms like Assessa, a secure digital tool that aids clinical decision-making for patient selection and post-market monitoring, and TrialTracker, which streamlines intricate imaging workflows, handling everything from initial image uploads and quality control to expert analysis, interpretation, and final data delivery within clinical research. IXICO's expertise is concentrated on neurological disorders, including Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating conditions, Progressive Supranuclear Palsy, and various rare neurological diseases. Their services encompass not only the collection, optimization, and analytics for rare neurological disorders but also drug development analytics, specialized imaging operations, post-market surveillance support, and expert consultancy. The company delivers comprehensive, end-to-end services for clinical trials, covering initial trial design and consultation, meticulous project management, imaging site setup and management, robust data management, expert image reading and analysis, and guidance on regulatory pathways.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Physiomics
―
Open Orphan Plc
―
Aptamer Group Plc
―









